Sangamo Therapeutics (SGMO) shares slumped over -30% lower due to a failed Phase 1/2 study. The company reported its SB-318 genome editing product did not appear to show any clinical benefits. The company does have an extensive pipeline of treatments in clinical trials, as well as partnerships with major companies such as Pfizer. However, this was not enough for traders to keep the price stable near yesterday’s close. Here’s a recap.
This week, Nvidia (NVDA) and tech positivity sustained market gains despite losses on Friday after Federal Reserve Chairman Kevin Warsh spoke and September interest rate-hike odds nearly doubled. INFLATION EXPECTATIONS MUST BE ‘CLOSELY MINDED’ It was his comments on inflation that arguably went the furthest to meet what some had seen as a gap in […]
Read Article
Mike Shorr sat down for another live Q&A with his trading room, and this one gets into the numbers most traders never share. His current swing positions, why he leans on one specific ticker, and exactly what his winners look like next to his losers.
Read Article
Mike Shorr sat down for a live Q&A with his trading room and fielded questions ranging from his signature Zone setup to how gamma exposure quietly shapes market moves. He breaks it all down in plain terms, no jargon left unexplained.
Read Article
Scott Bauer joined the IBKR Podcast this week to break down what moved markets last week and what investors need to watch heading into the next stretch of earnings season. From lagging inflation data to big tech CapEx concerns, Scott did not hold back.
Read Article
The Dow rose more than 1% to a record closing high on Thursday ahead of the long holiday weekend as a softer-than-expected U.S. jobs report eased worries about interest rate hikes, while another sharp drop in chipmaker stocks weighed on the Nasdaq. The second half of 2026 kicked off this week much the same as […]
Read Article
A renewed sell-off in technology stocks grabbed headlines this week. The Nasdaq index fell 4.5%, closing lower 5 days in a row, led by a large 5.5% decline in the so-called Magnificent 7 mega cap names. Meanwhile, the post IPO exuberance around SpaceX appears to be fading, with shares now down 25% from their peak. […]
Read ArticleWe choose to let our members and students speak for themselves. We do not actively solicit testimonials, no compensation has been paid for any testimonial, and testimonials are not necessarily representative of the experience of all students. All monetary claims made in testimonials that you see depicted in our marketing material have been verified by Prosper Trading Academy and attested to by the members that have given them. Verified testimonials encompass “experience” reviews that highlight the personal experiences of working with our team and “performance” testimonials where we verify trading success of students who have enrolled in our programs.Given the broad reach of the internet, testimonials and reviews of our programs that we have not been able to verify can be found on various websites across the internet which are beyond our editorial control. While we do very much enjoy hearing positive things from our students and it is critical to our mission that everyone is satisfied with their journey with Prosper, we encourage you to take both verified and unverified testimonials for what they are.